| Project/Area Number |
17590404
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | AICHI MEDICAL UNIVERSITY |
|---|
Principal Investigator |
YOKOCHI Takashi Aichi Medical University, Department of Microbiology and Immunology, Professor, 医学部, 教授 (20126915)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥2,300,000 (Direct Cost: ¥2,300,000)
|
|---|
| Keywords | lipopolysaccharide / endotoxin / doxorubicin / p53 / macrophage / apoptosis / anti-cancer drug / DNA damage |
|---|
| Research Abstract |
The effect of lipopolysaccharide (LPS) on doxorubicin (DXB)-induced cell death was studied by using mouse RAW 264.7 macrophage cells. Pretreatment with LPS at 10ng/ml prevented DXB-induced cell death and the inhibition was roughly dependent on the concentration of LPS. The 1 h post-treatment of LPS also prevented DXB-induced cell death. LPS inhibited DNA fragmentation and caspase 3 activation in DXB-treated RAW 264.7 cells, suggesting the prevention of DXB-induced apoptosis. LPS did not significantly inhibit DXB-induced DNA damages detected by a single cell gel electrophoresis (comet) assay. LPS definitely inhibited the stabilization and nuclear translocation of p53 in DXB-treated RAW 264.7 cells. LPS as well as an inhibitor of p53 abolished DXB-induced apoptosis. Therefore, p53 was suggested to play a pivotal role in the prevention of DXB-induced apoptosis in RAW 264.7 cells by LPS.
|
